Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2015

01-08-2015 | Research Article

Pharmacists’ role in handling problems with prescriptions for antithrombotic medication in Belgian community pharmacies

Authors: S. Desmaele, I. De Wulf, A. G. Dupont, S. Steurbaut

Published in: International Journal of Clinical Pharmacy | Issue 4/2015

Login to get access

Abstract

Background Community pharmacists have an important task in the follow-up of patients treated with antithrombotics. When delivering these medicines, pharmacists can encounter drug–related problems (DRPs) with substantial clinical and economic impact. Objective To investigate the amount and type of antithrombotic related DRPs as well as how community pharmacists handled these DRPs. Setting Belgian community pharmacies. Methods MSc pharmacy students of six Belgian universities collected data about all DRPs encountered by a pharmacist during ten half days of their pharmacy internship. Data were registered about DRPs detected at delivery and in an a posteriori setting, when consulting the medical history of the patient. Classification of the DRP, cause of the DRP, intervention and result of the intervention were registered. Main outcome measure Amount and type of antotrombitocs related DRPs occurring in community pharmacies, as well as how community pharmacists handled these DRPs. Results 3.1 % of the 15,952 registered DRPs concerned antithrombotics. 79.3 % of these DRPs were detected at delivery and 20.7 % were detected a posteriori. Most antithrombotic-related DRPs concerned problems with the choice of the drug (mainly because of drug–drug interactions) or concerned logistic problems. Almost 80 % of the antithrombotic-related DRPs were followed by an intervention of the pharmacist, mainly at the patient’s level, resulting in 90.1 % of these DRPs partially or totally solved. Conclusion Different DRPs with antithrombotic medication occurred in Belgian community pharmacies. About 20 % was detected in an a posteriori setting, showing the benefit of medication review. Many of the encountered DRPs were of technical nature (60.7 %). These DRPs were time-consuming for the pharmacist to resolve and should be prevented. Most of the DRPs could be solved, demonstrating the added value of the community pharmacist as first line healthcare provider.
Appendix
Available only for authorised users
Literature
1.
go back to reference Silva MV, Dusse LM, Vieira LM, Carvalho M. Platelet antiaggregants in primary and secondary prevention of atherothrombotic events. Arq Bras Cardiol. 2013;100(6):e78–84.PubMed Silva MV, Dusse LM, Vieira LM, Carvalho M. Platelet antiaggregants in primary and secondary prevention of atherothrombotic events. Arq Bras Cardiol. 2013;100(6):e78–84.PubMed
2.
go back to reference Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: a review of the pharmacology, dosing, and complications. Curr Emerg Hosp Med Rep. 2013;1(2):83–97.PubMedCentralPubMedCrossRef Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: a review of the pharmacology, dosing, and complications. Curr Emerg Hosp Med Rep. 2013;1(2):83–97.PubMedCentralPubMedCrossRef
3.
go back to reference Schneeweiss S, Hasford J, Gottler M, Hoffmann A, Riethling AK, Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58(4):285–91.PubMedCrossRef Schneeweiss S, Hasford J, Gottler M, Hoffmann A, Riethling AK, Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58(4):285–91.PubMedCrossRef
4.
go back to reference Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Drug-related hospital admissions: a review of Australian studies published 1988–1996. Med J Aust. 1998;168(8):405–8.PubMed Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Drug-related hospital admissions: a review of Australian studies published 1988–1996. Med J Aust. 1998;168(8):405–8.PubMed
5.
go back to reference Walsh D, Lavan A, Cushen AM, Williams D. Adverse drug reactions as a cause of admission to a Dublin-based university teaching hospital. Ir J Med Sci. 2014. Walsh D, Lavan A, Cushen AM, Williams D. Adverse drug reactions as a cause of admission to a Dublin-based university teaching hospital. Ir J Med Sci. 2014.
6.
go back to reference Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23(5):489–97.PubMedCrossRef Dechanont S, Maphanta S, Butthum B, Kongkaew C. Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2014;23(5):489–97.PubMedCrossRef
7.
go back to reference Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):546S–92S.PubMedCrossRef Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):546S–92S.PubMedCrossRef
8.
go back to reference Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J. 2010;74(11):2479–500. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): digest version. Circ J. 2010;74(11):2479–500.
9.
go back to reference Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.PubMedCrossRef Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.PubMedCrossRef
10.
go back to reference Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27(1):74–90.PubMedCrossRef Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011;27(1):74–90.PubMedCrossRef
11.
go back to reference Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl):e326S–50S.PubMedCentralPubMed Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl):e326S–50S.PubMedCentralPubMed
12.
go back to reference Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. Ocused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. Ocused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–47.
13.
go back to reference Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51.PubMedCrossRef Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51.PubMedCrossRef
15.
go back to reference Westerlund T, Gelin U, Pettersson E, Skarlund F, Wagstrom K, Ringbom C. A retrospective analysis of drug-related problems documented in a national database. Int J Clin Pharm. 2013;35(2):202–9.PubMedCrossRef Westerlund T, Gelin U, Pettersson E, Skarlund F, Wagstrom K, Ringbom C. A retrospective analysis of drug-related problems documented in a national database. Int J Clin Pharm. 2013;35(2):202–9.PubMedCrossRef
16.
go back to reference Westerlund T, Marklund B. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems. J Clin Pharm Ther. 2009;34(3):319–27.PubMedCrossRef Westerlund T, Marklund B. Assessment of the clinical and economic outcomes of pharmacy interventions in drug-related problems. J Clin Pharm Ther. 2009;34(3):319–27.PubMedCrossRef
17.
go back to reference Buurma H, De Smet PA, Leufkens HG, Egberts AC. Evaluation of the clinical value of pharmacists’ modifications of prescription errors. Br J Clin Pharmacol. 2004;58(5):503–11.PubMedCentralPubMedCrossRef Buurma H, De Smet PA, Leufkens HG, Egberts AC. Evaluation of the clinical value of pharmacists’ modifications of prescription errors. Br J Clin Pharmacol. 2004;58(5):503–11.PubMedCentralPubMedCrossRef
18.
go back to reference De Vriese C, Sansterre G, De Wulf I, Claeys C. Adaptation and validation of a drug related problem classification tool in community pharmacy. Int J Clin Pharm. 2013;35(3):497–8. De Vriese C, Sansterre G, De Wulf I, Claeys C. Adaptation and validation of a drug related problem classification tool in community pharmacy. Int J Clin Pharm. 2013;35(3):497–8.
19.
go back to reference van Noord E, van der Graaf C, de Gier J. Onderzoek naar prescriptie-interventies in een openbare apotheek. PW Wetenschappelijk Platform. 2009;3(6):6. van Noord E, van der Graaf C, de Gier J. Onderzoek naar prescriptie-interventies in een openbare apotheek. PW Wetenschappelijk Platform. 2009;3(6):6.
20.
go back to reference WHO. ATC/DDD Index. [Internet] Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2014 [updated 2013-12-19; cited 2014 2014-03-10]; Available from: http://www.whocc.no/. WHO. ATC/DDD Index. [Internet] Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2014 [updated 2013-12-19; cited 2014 2014-03-10]; Available from: http://​www.​whocc.​no/​.
Metadata
Title
Pharmacists’ role in handling problems with prescriptions for antithrombotic medication in Belgian community pharmacies
Authors
S. Desmaele
I. De Wulf
A. G. Dupont
S. Steurbaut
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 4/2015
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0106-3

Other articles of this Issue 4/2015

International Journal of Clinical Pharmacy 4/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.